Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia

The American Journal of Cardiology
Harold E BaysStacey Abby

Abstract

Elevated high-sensitivity C-reactive protein (hs-CRP) levels are associated with an increased risk of atherosclerotic coronary heart disease (CHD). The addition of the bile acid sequestrants, such as colesevelam hydrochloride (HCl), to statins further reduces low-density lipoprotein (LDL) cholesterol levels. However, the effects of approved cholesterol-lowering bile acid sequestrants on hs-CRP have not previously been reported. Three randomized, double-blind, placebo-controlled, parallel, 6-week clinical trials of similar design investigated the efficacy of adding colesevelam HCl to stable simvastatin, atorvastatin, or pravastatin treatment in 204 patients with primary hypercholesterolemia. The primary end point was the mean percent change in the LDL cholesterol levels. Secondary end points included the effects on other lipid parameters and hs-CRP levels. A pooled analysis showed that adding colesevelam HCl to statin therapy significantly lowered LDL cholesterol levels (21 mg/dl or 16% mean reduction from baseline, p = 0.0013, and 11 mg/dl or 9% mean reduction compared with placebo, p = 0.0003). Four times as many patients receiving colesevelam HCl plus a statin achieved a LDL cholesterol target of <100 mg/dl compared with pati...Continue Reading

References

Dec 19, 1990·JAMA : the Journal of the American Medical Association·J P KaneR J Havel
Jun 19, 1987·JAMA : the Journal of the American Medical Association·D H BlankenhornL Cashin-Hemphill
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Mar 19, 2002·The American Journal of Cardiology·Moti L KashyapPhillip D Simmons
May 25, 2002·Angiology·Evagelos RizosDimitri P Mikhailidis
May 13, 2003·Expert Opinion on Pharmacotherapy·Harold Bays, Carlos Dujovne
Nov 16, 2004·The American Journal of Cardiology·Joseph P FrolkisDennis L Sprecher
Oct 11, 2005·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·George U Liepa, Hemendra Basu

❮ Previous
Next ❯

Citations

Sep 10, 2008·European Journal of Drug Metabolism and Pharmacokinetics·Suncica Kojic-DamjanovSlavko Kevresan
Aug 28, 2012·Pharmaceutical Research·Stephen D LeeKishor M Wasan
Jul 9, 2011·Internal and Emergency Medicine·Franco ScaldaferriAntonio Gasbarrini
Apr 29, 2010·Current Atherosclerosis Reports·Parag H Joshi, Terry A Jacobson
Apr 29, 2010·Current Atherosclerosis Reports·Byron F Vandenberg, Jennifer Robinson
Sep 23, 2011·Current Cardiology Reports·B SjoukeG K Hovingh
Aug 6, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michael R Jones, Oliseyenum M Nwose
Dec 20, 2007·American Journal of Therapeutics·Harold E Bays, Ronald B Goldberg
Dec 22, 2011·Current Opinion in Lipidology·Carolien OutGemma Brufau
Oct 1, 2009·Diabetes, Obesity & Metabolism·D S H Bell, James H O'Keefe
Sep 24, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michael H DavidsonMichael R Jones
May 4, 2011·World Journal of Diabetes·Kohzo TakebayashiToshihiko Inukai
Apr 30, 2014·Drugs & Aging·James R GavinKenneth E Truitt
Nov 15, 2007·Current Cardiology Reports·Catherine Y CampbellRoger S Blumenthal
Jun 1, 2010·Expert Opinion on Pharmacotherapy·Konstantinos ToutouzasChristodoulos Stefanadis
Mar 20, 2015·Expert Opinion on Drug Metabolism & Toxicology·Aris P AgouridisDimitri P Mikhailidis
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Michael H Davidson
Jun 10, 2008·Expert Opinion on Emerging Drugs·Rebecca L PollexRobert A Hegele
Jan 14, 2011·Expert Opinion on Emerging Drugs·Tarek A N AhmedJ Wouter Jukema
Feb 18, 2011·Expert Opinion on Emerging Drugs·Matilda FlorentinMoses S Elisaf
Nov 2, 2006·Current Medical Research and Opinion·Harold BaysMichael Jones
Feb 6, 2009·Current Medical Research and Opinion·Alberico L Catapano
Feb 23, 2008·Current Medical Research and Opinion·M FlorentinM S Elisaf
Apr 27, 2011·The American Journal of the Medical Sciences·Carl J LavieJames H O'Keefe
Feb 7, 2012·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Lin-Zhang Huang, Hai-Bo Zhu
Mar 17, 2010·Pharmacology & Therapeutics·Philippe Costet
Aug 30, 2008·Journal of the American Medical Directors Association·Barbara J Messinger-RapportJohn E Morley
Mar 21, 2007·The American Journal of Cardiology·Terry A JacobsonJohn R Guyton
Nov 21, 2015·Canadian Journal of Diabetes·Supna SandhuGordon A Francis
Oct 10, 2014·Atherosclerosis·Alberico L CatapanoAndrew M Tershakovec
Feb 25, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Alberto CorsiniMichel Farnier
Aug 5, 2011·Journal of Pharmacy Practice·Luigi Brunetti, R Keith Campbell
Jun 17, 2010·The Annals of Pharmacotherapy·Luigi Brunetti, Evelyn R Hermes-Desantis
Oct 24, 2008·Current Opinion in Rheumatology·Georgirene D Vladutiu
Aug 18, 2009·Fundamental & Clinical Pharmacology·Zeljko Reiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.